Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis

Company Overview

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $33.99 to $33.99
• 50-Day Range: $33.63 to $33.99
• 52-Week Range: $17.00 to $39.30
• Volume: N/A
• Average Volume: 940,325 shs
• Market Capitalization: $1.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNST Stock Analysis - Frequently Asked Questions

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) announced its quarterly earnings data on Sunday, May, 9th. The company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $0.05.

When did Constellation Pharmaceuticals IPO?

Constellation Pharmaceuticals (CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Kinross Gold (KGC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Gilead Sciences (GILD) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 5/09/2021
• Today: 1/21/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CNST
• CUSIP: 21036U206
• CIK: 29806
• Web: www.constellationpharma.com
• Phone: 617-714-0555
• Fax: N/A
• Employees: 154
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-126,360,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.12%
• Return on Assets: -29.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.39
• Quick Ratio: 15.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.63 per share
• Price / Book: 3.94

Miscellaneous

• Outstanding Shares: 47,915,000
• Free Float: N/A
• Market Cap: $1.63 billion
• Optionable: Not Optionable
• Beta: 2.59